Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Similar
Filing Names

Deutsches Krebsforschungszentrum
Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts
Deutsches Krebsforschungszentrum Stiftung Des xd6 ffentlichen Rechts
Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts
Deutsches Krebsforschungszentrum Stiftung Des xf6 ffentlichen Rechts
Deutsches Krebsforschungszentrum Stiftung Des xd6 ffentlichen Rechtes
Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechtes
Deutsches Krebsforschungszentrum Stifting Des Offentlichen Rechts
Deutsches Krebsforschungszentrum Stiftung Des Offentlicen Rechts
Deutsches Krebsforschungszentrum Stiftung Des Offentilchen Rechts
Deutsches Krebsforschungszentrum Stiftung Des Oeffentichen Rechts
Deutsches Krebsforschungszentrum Stiftung Des Oeff
Deutsches Krebsforschungszentrum Stiftung Des xd6 ffe
Deutsches Krebsforschungszentrum Stiftung Des xf6 ffentkuchen Rechts
Deutsches Krebsforschungszentrum stiftung Des xd6 ffen
Deutsches Krebsforschungszentrum Stiftung Des xd6 ffetlichen Rechts
Deutsches Krebsforschungszentrum Stiftung Des xd6 ffentlichenrechts
Deutsches Krebsforschungszentrum Stiftung Des xd6 ffentlichen Recht
Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts_20100121

Deutsches Krebsforschungszentrum patents


Recent patent applications related to Deutsches Krebsforschungszentrum. Deutsches Krebsforschungszentrum is listed as an Agent/Assignee. Note: Deutsches Krebsforschungszentrum may have other listings under different names/spellings. We're not affiliated with Deutsches Krebsforschungszentrum, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "D" | Deutsches Krebsforschungszentrum-related inventors


Diagnostic transcript and splice patterns of hr-hpv in different cervical lesions

The present invention relates to a method for differentiating in a subject with hr-hpv between a severe form of hr-hpv infection and a mild form of hr-hpv infection. It further is concerned with a composition comprising a probe oligonucleotide mixture, a device, and a kit for use in conjunction with the method of the invention.. ... Deutsches Krebsforschungszentrum

Biomarker panel for diagnosing cancer

The present invention pertains to a new method for the diagnosis, prognosis, stratification and/or monitoring of a therapy, of cancer in a patient. The method is based on the determination of the level of a panel of biomarkers selected from cea, areg, il-6, gdf-15, hgf-receptor, cxcl9, erbb4-her4, cxclio, flt3l, vegfr-2, cd69, cxcl5s, psa, emmprin, cathepsin-d, caspase-3, tnf-alpha, and inf-gamma. ... Deutsches Krebsforschungszentrum

Oligonucleotide sequences targeting transcription factortsc22d4 for the treatment of insulin resistance

The present invention relates to oligonucleotide inhibitors of the tsc22d4 activity or expression and their uses for the prevention, treatment, and/or regulation of insulin resistance, metabolic syndrome and/or diabetes and/or for improving insulin sensitivity in a mammal.. . ... Deutsches Krebsforschungszentrum

Binding molecules, especially antibodies, binding to l1cam (cd171)

The present disclosure relates to a binding molecule binding to l1, which is capable of binding to the same l1 epitope recognized by the monoclonal antibody l1-ov52.24, and/or which competes with the monoclonal antibody l1-ov52.24 for binding to l1, wherein the variable part of the light chain of l1-ov52.24 comprises the sequence according to seq id no: 1 or wherein the light chain is encoded by seq id no: 3, and wherein the variable part of the heavy chain of l1-ov52.24 comprises the sequence according to seq id no: 2 or wherein the heavy chain is encoded by seq id no: 4, nucleic acids encoding the binding molecules, uses thereof and pharmaceutical compositions comprising the binding molecules.. . ... Deutsches Krebsforschungszentrum

Method for the detection of antigen presentation

The present invention pertains to a method for detecting antigen presentation via antigen presenting molecules such as major histocompatibility complex (mhc) class i or ii. The invention deploys a first binding agent specific for the antigen epitope and a second binding agent specific for the antigen presenting molecule. ... Deutsches Krebsforschungszentrum

Hcbi, msbi, mssi and cmi sequences as an early marker for the future development of cancer and diseases of the cns and as a target for the treatment and prevention of these diseases

Described are hcbi (healthy cattle blood isolate), msbi (multiple sclerosis brain isolate), mssi (multiple sclerosis serum isolate) and cmi (cow milk isolate) nucleotide sequences as well as probes and primers comprising part of said nucleotide sequences and antibodies against polypeptides encoded by said nucleotide sequences. Said compounds are useful as early markers for the future development of cancer and diseases of the cns (multiple sclerosis ms, prion-linked diseases, amyotrophic lateral sclerosis, transmissible spongiforme encephalitis, parkinson's disease, alzheimer disease) and should represent targets for treatment and prevention.. ... Deutsches Krebsforschungszentrum

Receptors of rspo2 and rspo3

The present invention relates to the finding that syndecans (sdc) are receptors of rspondin-2 (rspo2) and rspondin-3 (rspo3). Thus, the present invention relates to the identification of rspo2, rspo3 and/or sdc activity modulators by determining if a test compound has the ability to modulate the binding of an rspo2 and/or rspo3 polypeptide to an sdc polypeptide. ... Deutsches Krebsforschungszentrum

Methods for the prediction of a personalized esa-dose in the treatment of anemia

The present invention pertains to the use of an integrative pharmacokinetic/pharmacodynamic (pk/pd) esa-epor mathematical model for calculating the binding behaviour of erythropoiesis stimulating agents (esa). The invention provides methods for the determining of esa binding sites in cells or patients suffering from anemia. ... Deutsches Krebsforschungszentrum

S100p and hyaluronic acid as biomarkers for metastatic breast cancer

The present invention pertains to a new method for the diagnosis, prognosis, stratification and/or monitoring of a therapy, of breast cancer in a patient. The method is based on the use of hyaluronic acid and s100p as combined biomarkers in the plasma of breast cancer patients. ... Deutsches Krebsforschungszentrum

Inhibitors of thioredoxin-interacting protein (txnip) for therapy

Described is a compound capable of reducing or inhibiting (a) the biological activity of thioredoxin-interacting protein (txnip) or (b) the expression of the gene encoding txnip for treating a condition where improving the resistance towards oxidative stress has a beneficial effect, e.g., for improving female fertiliy or extending healthy lifespan.. . ... Deutsches Krebsforschungszentrum








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Deutsches Krebsforschungszentrum in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Deutsches Krebsforschungszentrum with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###